Effects of genetic liability to Alzheimers disease on circulating metabolites across the life course

Objective: Alzheimers disease (AD) has several known genetic determinants, yet the mechanisms through which they lead to disease onset remain poorly understood. This study aims to estimate the effects of genetic liability to AD on plasma metabolites measured at seven different stages across the life course. Methods: Genetic and metabolomic data from 5,648 offspring from the Avon Longitudinal Study of Parents and Children birth cohort were used. Linear regression models examined the association between higher AD liability, as measured by a genetic risk score (GRS), and plasma metabolites measured at 8, 16, 18 and 25 years of age. Two hundred twenty-nine metabolites were studied, most relating to lipid/lipoprotein traits. Two-sample Mendelian randomization was performed using summary statistics from age-stratified genome-wide association studies (GWAS) of the same metabolites for 118,466 participants from the UK Biobank, to examine the persistence of any AD liability effects into late adulthood. Results: The GRS including the APOE4 isoform demonstrated the strongest positive associations for cholesterol-related traits per doubling of genetic liability to AD, e.g., for low-density lipoprotein cholesterol (LDL-C) at age 25yrs (0.12 SD; 95% CI 0.09, 0.14), with similar magnitudes of association across age groups in ALSPAC. In the UK Biobank, the effect of AD liability decreased with age tertile for several lipid traits (e.g., LDL-C, youngest: 0.15 SD; 95% CI 0.07, 0.23, intermediate: 0.13 SD; 95% CI 0.07, 0.20, oldest: 0.10 SD; 95% CI 0.05, 0.16). Across both cohorts, the effect of AD liability on high-density lipoprotein cholesterol (HDL-C) attenuated as age increased. Fatty acid metabolites also demonstrated positive associations in both cohorts, though smaller in magnitude compared with lipid traits. Sensitivity analyses indicated that these effects were driven by the APOE4 isoform. Conclusions: These results support a profound influence of the APOE4 isoform on circulating lipids and fatty acids from early life to later adulthood. Such lipid and fatty acid traits may be implicated in early AD pathogenesis and warrant further investigation as potential targets for preventing the onset of AD.

[1]  Laurent F. Thomas,et al.  A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer’s disease , 2021, Nature Genetics.

[2]  R. Dobson,et al.  Mendelian randomization identifies blood metabolites previously linked to midlife cognition as causal candidates in Alzheimer’s disease , 2021, Proceedings of the National Academy of Sciences.

[3]  E. Ware,et al.  Type 2 Diabetes and Cognitive Status in the Health and Retirement Study: A Mendelian Randomization Approach , 2021, Frontiers in Genetics.

[4]  Ariel K. Frame,et al.  Determining the role of lactate metabolism on age‐dependent memory decline and neurodegeneration in Drosophila melanogaster , 2020, Alzheimer's & Dementia.

[5]  Weiqi Chen,et al.  Glycemic traits and Alzheimer’s disease: a Mendelian randomization study , 2020, Aging.

[6]  G. Bu,et al.  APOE2: protective mechanism and therapeutic implications for Alzheimer’s disease , 2020, Molecular Neurodegeneration.

[7]  Matthew S. Gentry,et al.  APOE4 Lowers Energy Expenditure and Impairs Glucose Oxidation by Increasing Flux through Aerobic Glycolysis , 2020, bioRxiv.

[8]  Jie Zan,et al.  Untargeted lipidomics reveals progression of early Alzheimer’s disease in APP/PS1 transgenic mice , 2020, Scientific Reports.

[9]  Valeriia Haberland,et al.  The MRC IEU OpenGWAS data infrastructure , 2020, bioRxiv.

[10]  J. Tolstrup,et al.  Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals , 2020, Epidemiology and Psychiatric Sciences.

[11]  D. Michaelson,et al.  Central and Peripheral Mechanisms in ApoE4-Driven Diabetic Pathology , 2020, International journal of molecular sciences.

[12]  James R. Staley,et al.  A robust and efficient method for Mendelian randomization with hundreds of genetic variants , 2020, Nature Communications.

[13]  Matthew S. Gentry,et al.  APOE alters glucose flux through central carbon pathways in astrocytes , 2020, Neurobiology of Disease.

[14]  M. Delorenzi,et al.  Systemic and central nervous system metabolic alterations in Alzheimer’s disease , 2019, Alzheimer's Research & Therapy.

[15]  D. Bennett,et al.  Brain and blood metabolome for Alzheimer's dementia: findings from a targeted metabolomics analysis , 2019, Neurobiology of Aging.

[16]  N. Timpson,et al.  Early Metabolic Features of Genetic Liability to Type 2 Diabetes: Cohort Study With Repeated Metabolomics Across Early Life , 2019, Diabetes Care.

[17]  D. Hervás,et al.  Plasma metabolomics in early Alzheimer's disease patients diagnosed with amyloid biomarker. , 2019, Journal of proteomics.

[18]  Tom R. Gaunt,et al.  The Avon Longitudinal Study of Parents and Children (ALSPAC): an update on the enrolled sample of index children in 2019 , 2019, Wellcome open research.

[19]  G. Davey Smith,et al.  Can Mendelian Randomization Shift into Reverse Gear? , 2019, Clinical chemistry.

[20]  Eden R Martin,et al.  Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing , 2019, Nature Genetics.

[21]  Hemani,et al.  MRC IEU UK Biobank GWAS pipeline version 2 , 2019 .

[22]  D. Lawson,et al.  Apparent latent structure within the UK Biobank sample has implications for epidemiological analysis , 2019, Nature Communications.

[23]  O. Andreassen,et al.  Dissecting the genetic relationship between cardiovascular risk factors and Alzheimer’s disease , 2018, Acta Neuropathologica.

[24]  M. Weiner,et al.  Serum triglycerides in Alzheimer’s disease: Relation to neuroimaging and CSF biomarkers , 2018, bioRxiv.

[25]  Jason Weller,et al.  Current understanding of Alzheimer’s disease diagnosis and treatment , 2018, F1000Research.

[26]  G. Davey Smith,et al.  Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians , 2018, British Medical Journal.

[27]  Valeriia Haberland,et al.  The MR-Base platform supports systematic causal inference across the human phenome , 2018, eLife.

[28]  S. Burgess,et al.  Mendelian randomization with a binary exposure variable: interpretation and presentation of causal estimates , 2018, European Journal of Epidemiology.

[29]  L. Ferrucci,et al.  Evidence for brain glucose dysregulation in Alzheimer's disease , 2018, Alzheimer's & Dementia.

[30]  C. Rowe,et al.  High performance plasma amyloid-β biomarkers for Alzheimer’s disease , 2018, Nature.

[31]  A. Saykin,et al.  Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study , 2018, PLoS medicine.

[32]  A. Sayago,et al.  Metabolomics in Alzheimer's disease: The need of complementary analytical platforms for the identification of biomarkers to unravel the underlying pathology. , 2017, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[33]  Hugh S. Markus,et al.  Branched-chain amino acids and Alzheimer’s disease: a Mendelian randomization analysis , 2017, Scientific Reports.

[34]  Michael W. Weiner,et al.  Metabolic network failures in Alzheimer's disease: A biochemical road map , 2017, Alzheimer's & Dementia.

[35]  L. Farde,et al.  Differential Effect of APOE Alleles on Brain Glucose Metabolism in Targeted Replacement Mice: An [18F]FDG-μPET Study , 2017, Journal of Alzheimer's disease reports.

[36]  R. Xiao,et al.  ApoE rs429358 and rs7412 Polymorphism and Gender Differences of Serum Lipid Profile and Cognition in Aging Chinese Population , 2017, Front. Aging Neurosci..

[37]  Cathie Sudlow,et al.  UK Biobank: opportunities for cardiovascular research , 2017, European heart journal.

[38]  Debbie A Lawlor,et al.  Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies , 2017, American journal of epidemiology.

[39]  G. Corso,et al.  Serum Amino Acid Profiles in Normal Subjects and in Patients with or at Risk of Alzheimer Dementia , 2017, Dementia and Geriatric Cognitive Disorders Extra.

[40]  Y. An,et al.  Association between fatty acid metabolism in the brain and Alzheimer disease neuropathology and cognitive performance: A nontargeted metabolomic study , 2017, PLoS medicine.

[41]  Stephen Burgess,et al.  Sensitivity Analyses for Robust Causal Inference from Mendelian Randomization Analyses with Multiple Genetic Variants , 2016, Epidemiology.

[42]  Inês Barroso,et al.  Genetic Predisposition to an Impaired Metabolism of the Branched-Chain Amino Acids and Risk of Type 2 Diabetes: A Mendelian Randomisation Analysis , 2016, PLoS medicine.

[43]  V. Gudnason,et al.  Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals , 2016, Alzheimer's & Dementia.

[44]  K. Blennow,et al.  CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis , 2016, The Lancet Neurology.

[45]  G. Davey Smith,et al.  Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator , 2016, Genetic epidemiology.

[46]  C. Itsiopoulos,et al.  Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer's Disease , 2015, BioMed research international.

[47]  P. Calder,et al.  Functional Roles of Fatty Acids and Their Effects on Human Health. , 2015, JPEN. Journal of parenteral and enteral nutrition.

[48]  Michael T. Heneka,et al.  Innate immune activation in neurodegenerative disease , 2014, Nature Reviews Immunology.

[49]  Derick R. Peterson,et al.  Plasma phospholipids identify antecedent memory impairment in older adults , 2014, Nature Medicine.

[50]  C. DeCarli,et al.  Associations between serum cholesterol levels and cerebral amyloidosis. , 2014, JAMA neurology.

[51]  Huaxi Xu,et al.  Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy , 2013, Nature Reviews Neurology.

[52]  D. Lawlor,et al.  Cohort Profile: The Avon Longitudinal Study of Parents and Children: ALSPAC mothers cohort , 2012, International journal of epidemiology.

[53]  D. Lawlor,et al.  Cohort Profile: The ‘Children of the 90s’—the index offspring of the Avon Longitudinal Study of Parents and Children , 2012, International journal of epidemiology.

[54]  P. Calder Fatty acids and inflammation: the cutting edge between food and pharma. , 2011, European journal of pharmacology.

[55]  H. Arrighi,et al.  Apolipoprotein E ε4 Prevalence in Alzheimer’s Disease Patients Varies across Global Populations: A Systematic Literature Review and Meta-Analysis , 2010, Dementia and Geriatric Cognitive Disorders.

[56]  Constantine G. Lyketsos,et al.  Alterations of the Sphingolipid Pathway in Alzheimer’s Disease: New Biomarkers and Treatment Targets? , 2010, NeuroMolecular Medicine.

[57]  L. Ferrucci,et al.  Relationship between low levels of high-density lipoprotein cholesterol and dementia in the elderly. The InChianti study. , 2010, The journals of gerontology. Series A, Biological sciences and medical sciences.

[58]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[59]  Tom R. Gaunt,et al.  Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip. , 2009, American journal of human genetics.

[60]  M. Hayden,et al.  Elevated plasma triglyceride levels precede amyloid deposition in Alzheimer’s disease mouse models with abundant Aβ in plasma , 2006, Neurobiology of Disease.

[61]  G. Alexander,et al.  Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[62]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[63]  H. Sørensen,et al.  Research in Health Care , 1996 .

[64]  W. M. van der Flier,et al.  Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. , 2017, Journal of Alzheimer's disease : JAD.

[65]  S. Snowden,et al.  Metabolic Modifications in Human Biofluids Suggest the Involvement of Sphingolipid, Antioxidant, and Glutamate Metabolism in Alzheimer's Disease Pathogenesis. , 2015, Journal of Alzheimer's disease : JAD.

[66]  Y. Hannun,et al.  An overview of sphingolipid metabolism: from synthesis to breakdown. , 2010, Advances in experimental medicine and biology.